



www.methapharm.com

Methapharm Inc.

CUSTODIOL®

HTK Solution

The Cold Standard

"Learn from yesterday, live for today, hope for tomorrow." - Anon.

Volume 1, Issue 2

March 14, 2007

DCD Transplantation: A Single Center European Experience

A recent study from the UK showed no significant differences between DCD and deceased kidney transplant outcomes at 1, 3, and 6 years post-transplantation.

Dr. Aliu Sanni from the Freeman Hospital retrospectively looked at the long-term outcomes of the first 100 DCD kidney transplants compared with the next consecutive deceased donor kidneys for graft survival, recipient survival and quality of graft function.

Recipient survival and graft survival at 6 years did not differ between recipients of DCD (83%, 80%) and deceased donor (89% and 87%) kidneys.

All DCD kidneys were perfused with CUSTODIOL® HTK solution with 1.5 million – unit streptokinase pre-flush.

The study bolsters previous findings that long term renal outcomes from DCD kidneys are comparable to that of deceased donor kidney transplants.

Update on DCD Transplantation in Canada

The Trillium Gift of Life Network adopted DCD in March of 2006 as part of its plan to increase organ donations.

Since then, the practice of DCD continues to increase in Canada, as more transplant centres adopt the procedure. As of June 2006, there have been 10 DCD donations in Ontario with the first eight taking place at teaching hospitals. Recently, the first DCD case from a community hospital was performed in Kitchener Ontario.

Furthering the DCD cause, the CCTD has adopted the benchmark set by the Department of Health and Human Services in the US, which is to have 20 per cent of all donations be after cardiac death.

With 172 deceased donors in Ontario in 2006 and at 1.4% of all deaths, organ donation remains relatively rare. The 20 per cent benchmark would provide an additional 35 organ donors per year in Ontario alone.

The Right Solution for DCD

CUSTODIOL® HTK has been the flush solution of choice for all 10 Canadian DCD donor cases to date.

CUSTODIOL® HTK provides a low viscosity similar to that of water, giving a more complete fast cold flush which is thought to be a major advantage when flushing DCD donor organs.

The low viscosity has been shown to reduce the risk of biliary complications in liver transplantation and provide

protection against delayed graft function in kidney transplantation.

CUSTODIOL® HTK is available in 1, 2, and now 5L bags for greater convenience when dealing with the larger flush volumes associated with DCD multi-organ donors. No more multi-bag switches....just hang, spike, and flush.

For further information please contact Rob Sanderson at 1.800.287.7686 x7231, to discuss how we can tailor a program with CUSTODIOL® HTK for your transplant center.



Remember...a little goes a long way and there's no advantage to overflushing

Transplantation Meeting Calendar

April 22–29, 2007

National Organ Donor & Tissue Donation Awareness Week

May 5–9, 2007

American Transplant Congress 2007

Moscone West Convention Center
San Francisco, CA

June 12–15, 2007

AOPO 24th Annual Meeting

Fairmont Hotel
Dallas, TX

Do you have a suggestion for a topic to use in our future newsletters? Please contact Rob Sanderson at 1.800.287.7686 x 7231

CUSTODIOL® HTK is the registered trademark of Dr. Franz Köhler Chemie GmbH, and is marketed in Canada by Methapharm Inc., in Brantford, Ontario